NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-081-2013-4-US-02 PREFUSION RSV F PROTEINS AND THEIR USE US CON 19/005,704 Pending
NCATS E-113-2023-0-EP-01 MULTI-CYCLC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF EP National Stage 23824825.6 Pending
NCI E-238-2017-0-US-02 METHODS OF ENRICHING CELL POPULATIONS FOR CANCER-SPECIFIC T CELLS USING IN VITRO STIMULATION OF MEMORY T CELLS US DIV 19/004,939 Pending
NCI E-129-2022-0-CA-01 CD25-SPECIFIC ANTIBODIES AND USES THEREOF CA National Stage 3260932 Pending
NCI E-186-2022-0-IN-01 PREDICTING PATIENT RESPONSE TO CANCER THERAPY VIA HISTOPATHOLOGY IMAGES IN National Stage 202417104351 Pending
NCI E-129-2022-0-JP-01 CD25-SPECIFIC ANTIBODIES AND USES THEREOF JP National Stage 2024-577174 Pending
NEI E-026-2025-0-US-01 SYSTEMS AND METHODS FOR AN ARTIFICIAL INTELLIGENCE BASED WORKFLOW ASSISTANT FOR SINGLE CELL ANALYSIS US 63/739,320 Expired
NCI E-190-2024-0-PC-01 CONSTRUCTS TARGETING MSLN PEPTIDE/MHC COMPLEXES AND USES THEREOF PCT PCT PCT/US2024/062156 Pending
NCI E-189-2024-0-PC-01 CONSTRUCTS TARGETING MSLN PEPTIDE/MHC COMPLEXES AND USES THEREOF PCT PCT PCT/US2024/062127 Pending
NIAID E-197-2023-0-US-04 Anti-SARS-COV-2 Antigen Binding Polypeptides, Polypeptide Complexes and Methods of Use Thereof US National Stage 18/879,056 Pending
NIAID E-197-2023-1-CL-01 ANTI-SARS-CoV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF [COM5] CL National Stage 202404032 Pending
NIBIB E-118-2022-0-CN-01 MICROFLUIDIC DEVICES FOR EVALUATING FIBROSIS IN MATERIAL IMPLANTATION AND CANCER CN National Stage 202380049880.9 Abandoned
NCI E-068-2018-0-AU-01 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 AU DIV 2024287198 Pending
NCI E-129-2022-0-US-02 CD25-SPECIFIC ANTIBODIES AND USES THEREOF US National Stage 18/878,317 Pending
NCI E-118-2024-0-US-02 AUGMENTING MITOCHONDRIA IN IMMUNE CELLS FOR IMPROVED CANCER IMMUNOTHERAPY US National Stage 18/878,307 Pending
NHLBI E-100-2022-0-IL-01 VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS (VLCPUFA) FOR IMPROVING RETINA/COGNITIVE FUNCTIONS AND ATHEROSCLEROSIS IL National Stage 317952 Pending
NIAID E-197-2023-1-IL-01 ANTI-SARS-CoV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF [COM5] IL National Stage 317895 Pending
NHLBI E-100-2022-0-EP-01 VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS (VLCPUFA) FOR IMPROVING RETINA/COGNITIVE FUNCTIONS AND EP National Stage 23750816.3 Pending
NCATS E-094-2024-0-PC-01 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF PCT PCT PCT/US2024/061453 Pending
NIAID E-140-2022-0-US-02 Dual-Germline Antibody Engager HIV-1 Envelope Chimeric Immunogens US National Stage 18/877,963 Pending
NCI E-129-2022-0-AU-01 CD25-SPECIFIC ANTIBODIES AND USES THEREOF AU National Stage 2023299296 Pending
NIAID E-215-2023-0-PC-01 Broadly Neutralizing Antibodies Against SARS-CoV-2 and SARS-CoV Variants PCT PCT PCT/US2024/061040 Pending
NLM E-107-2010-2-US-45 METHODS OF EPIGENETIC ANALYSIS US CON 18/986,315 Pending
NLM E-111-2022-2-EP-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM EP National Stage 23738969.7 Pending
NCI E-250-2016-0-US-02 METHODS OF PREPARING AN ISOLATED OR PURIFIED POPULATION OF THYMIC EMIGRANT CELLS AND METHODS OF TREATMENT USING SAME US DIV 18/985,707 Pending
NCI E-023-2024-0-US-01 VIRUS ANTIGEN-DERIVED IMMUNOGENIC PEPTIDES AND THEIR USE FOR THE PREVENTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA US 63/735,040 Expired
NCI E-172-2022-0-EP-01 SMALL CELL LUNG CANCER SUBTYPING USING PLASMA CELL-FREE NUCLEOSOMES EP National Stage 23807180.7 Pending
NIAID E-197-2023-0-CA-01 ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF CA National Stage 3259865 Pending
NCATS E-262-2023-0-PC-01 TRIAZOLONE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE AND THEIR THERAPEUTIC USE PCT PCT PCT/US2024/060337 Pending
NCATS E-246-2023-0-PC-01 INHIBITORS OF THE SURFACE EXPRESSION OF THE VOLTAGE-GATED SODIUM ION CHANNEL 1.7 (NaV1.7) AND THEIR THERAPEUTIC USES PCT PCT PCT/US2024/060335 Pending
NIAID E-139-2006-0-US-03 Development Of Dengue Virus Vaccine Components US CON 18/982,378 Pending
NICHD E-062-2015-0-US-02 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS US DIV 18/982,427 Pending
NIAID E-197-2023-1-MX-01 ANTI-SARS-CoV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF [COM5] MX National Stage MX/a/2024/015643 Pending
NIAID E-209-2023-0-PC-01 RSV VACCINE BEARING NS1, P, OR M2-1 GENE MUTATIONS PCT PCT PCT/US2024/059997 Pending
NCI E-185-2019-0-CN-01 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors CN DIV 202411838920.0 Pending
NCI E-158-2022-0-EP-01 IMMUNOGENS AND METHODS FOR INDUCING AN IMMUNE RESPONSE EP National Stage 23742608.5 Pending
NIAID E-044-2024-0-US-01 COMPOSITIONS AND METHODS FOR EDITING THE HUMAN ALPHA KINASE 1 (ALPK1) GENE AND TREATING ROSAH SYNDROME US 63/733,836 Expired
NCATS E-113-2023-0-US-02 MULTI-CYCLC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF US National Stage 18/874,609 Pending
NIAID E-001-2024-0-US-06 Viral Strain Serology Assays US National Stage 18/874,674 Pending
NIA E-135-2022-1-US-02 MONOCLONAL ANTIBODIES DIRECTED TO PHOSPHORYLATED PSD95 AND USES THEREOF US National Stage 18/874,359 Pending
NCI E-158-2022-0-US-02 IMMUNOGENS AND METHODS FOR INDUCING AN IMMUNE RESPONSE US National Stage 18/874,188 Pending
NCATS E-113-2023-0-JP-01 MULTI-CYCLC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF JP National Stage 2024-573290 Pending
CC E-230-2023-0-PCT-01 SYSTEMS AND METHODS FOR CLINICAL ARTIFICIAL INTELLIGENCE WITH PATIENT REPORTED MULTI-MODAL AUDIO DATA PCT PCT PCT/US2024/059680 Pending
NIAID E-131-2015-2-US-51 NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE US CON 18/977,802 Pending
NHGRI E-185-2014-0-US-02 VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER US CON 18/976,790 Pending
NCI E-245-2024-0-US-01 MESOTHELIN-TARGETED CAR T CELLS WITH INCREASED ANTI-TUMOR EFFICACY,
PERSISTENCE AND RESILIENCE AND USE THEREOF FOR THE TREATMENT OF MESOTHELINPOSITIVE CANCERS 		US 63/730,757 Expired
NIAID E-139-2024-0-US-01 Engineered influenza neuraminidase with altered catalytic activity US 63/730,558 Expired
NIAAA E-110-2022-0-US-02 TREATMENT OF FIBROTIC DISORDERS WITH METABOTROPIC GLUTAMATE RECEPTOR 5
ANTAGONISTS OR/AND CANNABINOID RECEPTOR 1 ANTAGONISTS 		US National Stage 18/873,511 Pending
NIAID E-057-2011-2-US-08 VIRUS-LIKE PARTICLES AND METHODS OF USE US CON 18/975,072 Pending
NCI E-031-2024-0-US-02 TREATMENT OF ALVEOLAR SOFT PART SARCOMA (ASPS) WITH ATEZOLIZUMAB US ORD 18/974,439 Pending